Dr. Sarah Holstein on Lenalidomide Maintenance Updates

Sarah Holstein, MD, PhD
Published: Tuesday, Sep 01, 2015



Sarah Holstein, MD, PhD, Assistant Professor of Oncology, Lymphoma/Myeloma Service Department of Medicine, Roswell Park Cancer Institute, discusses an updated of analysis CALGB/ECOG/BMT CTN 100104, which investigated lenalidomide maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma.

The updated analysis followed-up with patients after a medium of 65 months, compared to a medium of 34 months in the original study. After the extended follow-up, lenalidomide continued to show benefit, says Holstein. Time to progression in the lenalidomide arm was twice as long after extended follow-up compared to the original study results. .

There was also a continued significant improvement in overall survival (OS) in the lenalidomide arm after longer follow-up. Median OS has not yet been reached in that arm. Benefit after longer follow-up was seen in both patients who previously received lenalidomide or thalidomide as induction therapy. .



Sarah Holstein, MD, PhD, Assistant Professor of Oncology, Lymphoma/Myeloma Service Department of Medicine, Roswell Park Cancer Institute, discusses an updated of analysis CALGB/ECOG/BMT CTN 100104, which investigated lenalidomide maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma.

The updated analysis followed-up with patients after a medium of 65 months, compared to a medium of 34 months in the original study. After the extended follow-up, lenalidomide continued to show benefit, says Holstein. Time to progression in the lenalidomide arm was twice as long after extended follow-up compared to the original study results. .

There was also a continued significant improvement in overall survival (OS) in the lenalidomide arm after longer follow-up. Median OS has not yet been reached in that arm. Benefit after longer follow-up was seen in both patients who previously received lenalidomide or thalidomide as induction therapy. .


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x